Rudyanto M, Ekowati J, Widiandani T, Syahrani A.
In vivo anticancer activity of benzoxazine and aminomethyl compounds derived from eugenol.
J Public Health Afr 2023;
14:2511. [PMID:
37492555 PMCID:
PMC10365666 DOI:
10.4081/jphia.2023.2511]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 12/31/2022] [Indexed: 03/18/2023] Open
Abstract
Background
Indonesia is the world's primary producer of clove. In order to find new utilization for clove and new biologically active compounds, eugenol, the main constituent of clove, has been converted to its derivatives.
Objective
This study aims to examine in vivo anticancer activity of benzoxazine and aminomethyl compounds derived from eugenol.
Methods
Fibrosarcoma was induced by injection of benzo(a)pyrene solution. The test compounds were given per oral at 20, 40, and 80 mg/Kg body weight, once a day for 30 days.
Results
As a result, all the tested compounds showed activity in reducing the cancer incidence rate. All the tested compounds were also found to reduce tumor weight. Benzoxazine derivatives gave slightly better activity compared to aminomethyl derivatives. The strongest activity was exhibited by 6-allyl-3-(furan-2- ylmethyl)-8-methoxy-3,4-dihydro-2H-benzo(e)(1,3)oxazine.
Conclusions
All four benzoxazine and aminomethyl compounds derived from eugenol that were tested exhibited anticancer activity in mice fibrosarcoma.
Collapse